ArticleResearch and practice in thrombosis and haemostasis2026
A novel biosensor for measuring plasmin activity.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Plasmin facilitates fibrinolysis by catalyzing the degradation of fibrin clots. Reliable methods to assess fibrinolysis by measuring plasmin generation are needed in the preclinical and clinical settings. Objectives: This study aimed to design, synthesize, and evaluate a fluorescence resonance energy quenching-based plasmin sensor (FPS) protein to monitor plasmin generation. Methods: The hydrolysis of FPS was monitored by loss of fluorescence resonance energy quenching to evaluate efficiency and specificity. Plasma-based plasmin generation assays were used to evaluate fibrinolytic cofactors and inhibitors. Results: Compared with a peptide plasmin sensor, FPS demonstrated higher efficiency for plasmin and was not cleaved by plasmin inhibited by α Conclusion: FPS may improve the evaluation of fibrinolysis in preclinical and clinical settings, thereby enhancing our understanding of fibrinolytic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.